US1830313A - Synergized hypnotic and sedative - Google Patents

Synergized hypnotic and sedative Download PDF

Info

Publication number
US1830313A
US1830313A US270806A US27080628A US1830313A US 1830313 A US1830313 A US 1830313A US 270806 A US270806 A US 270806A US 27080628 A US27080628 A US 27080628A US 1830313 A US1830313 A US 1830313A
Authority
US
United States
Prior art keywords
magnesium
drug
hypnotic
sedative
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US270806A
Inventor
Moses L Crossley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CALCO CHEMICAL CO Inc
CALCO CHEMICAL COMPANY Inc
Original Assignee
CALCO CHEMICAL CO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CALCO CHEMICAL CO Inc filed Critical CALCO CHEMICAL CO Inc
Priority to US270806A priority Critical patent/US1830313A/en
Application granted granted Critical
Publication of US1830313A publication Critical patent/US1830313A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • My invention relates particularly to improved pharmaceuticals having enhanced economic value and ,more extended use in chemotherapyfbut especiall it has relation to improvedhypnotics an sedatives containing one or more magnesium compounds which synergize the drugs present.
  • the object f my invention is to provide improved pharmaceuticals, and particularly those used because of their hypnotic and se-;i dative properties, inwhich the drugs have.
  • the object of my invention is; more particularly, furthermore, to
  • the composition made in accordance with my invention containsin a drug of thelbarbituric acid series, the ormula for barbituricacid being which, by reason ofthe presence of a magnesium compound will produce their own therapeutic eflects with much less of the drug and in a shorter time than in the case of the unpotentiated drug. It is found, furthermore, that in using the composition made in accordance with my invention, the narcosis which results from the drug is less prolonged than with the unpotentiated drug. Also, the composition is less toxic in therapeutic doses than with the unpotentiated drug.
  • hypnotic and sedative rugs such as the drugs of the barbituric acid series,oneexample of which is bartital or some other hypnotic and-sedative such as bromatone, bromural, carbromal, chloral, sulfonal, etc., and containing one or more magnesium compounds as above referred to, such, for example, as
  • magnesium oxide, magnesium lactate, margnesium gluconate, etc.,I may use other ad tionaL compositions which may or may not have a therapeutic effect.
  • substances which may be added to enhance the absorptive properties of the composition are, for example, ethyl alcohol, glycerol, glycol, etc.
  • the magnesium compound ma vary in amount through wide limits, but I ave found very effective results .to be obtained by the use of the magnesium compound in an amount in which the magnesium present is at least 25% by weight of the, weight of the drug present.
  • an effective composition made in accordance with my invention may contain 2 parts by weight of magnesium chloride and 1 part *by' weight of sodium barbital,
  • the proportion of the'magnesium compound used may be widely varied and may, for exam le, be increased to as large a quantity as found efiective for the purpose desired, or substituted by any other Imagnesium compound as above described.
  • any other one of the hypnotic and sedative drugs may be substituted for the barbital, if desired.
  • the composition above described, as well as those hereinafter referred to, or their components may be administered per os, they may be administered in any other way, as, for
  • synergic compositions may be made of the above character, but containing, also, some substance to increase the absorption, as, for example, aloohol, glycerine or glycol or some other suitable polyhydroxyl alcohol.
  • a compositionof this character may be comprised of 0.2 parts by weight of sodium barbital, 0.4 parts by weight of magnesium' cbloride, and 30 parts by weight of- 2 2%" alcohol. If desired, there maybe added, also, 10'parts by weight of a sweetening agent, such as sucrose syrup.
  • any other hypnotic and sedative drug . may be substituted for the sodium barbital.
  • any other one of the above mentioned magnesium compounds may be substituted in an equivalent quantity for the magnesium chloride, and thatthe quantity of the magnesium compound may be varied. in the manner referred to in the above mentioned compositions.
  • the alcohol may be substituted by any other one of the substances'hereinabove referred to for increasing the absorption of the composition.
  • any of the above constituents may be substituted by others of a similar character for similar purposes.
  • Synergic compositions of the above character are particularly effective in. the case of insomnia .and similar maladies.
  • a pharmaceutical product comprising a synergic composition containing a magnesium compound and a synthetic hypnotic and sedative drug, the them utic properties of which are increased by t e magnesium com-- pound.
  • a pharmaceuticalproduct comprising a synergic composition containing a magnesium compound and a drug of the barbituric acid group, the therapeutic properties of which are lncreased pound.
  • a pharmaceutical product comprising a synergic composition containing a magneslum compound and barbital, the therapeutic properties of which are creased by the magnesium compound.
  • Apharmaceutical product comprising a synerg c compositioncontainin magnesium chloride, a drug of the barbitune acid group,
  • the therapeutic properties of which are m-- creased by the magnesium chloride, and an aliphatic alcohol.
  • a pharmadeutical product comprising ⁇ ; synergic. composition containin magnesium c loride,barbital, the therapeutic PFP of which are mcreasedby chloride, and an aliphatic alcohol.
  • a pharmaceutical product comprising a synergiccompos'ition containing a magne ,the magnesium sium com ound and a synthetic hypnotic and sedativeug, the-thera eufic properties of which are increased by the magnesium com- I pound,the magnesium compound bein pres- 5 cut in an al'nout such that the-magneslum is at least 25% by weight of the drug present.
  • a pharmaceutical product comprising a er ic composition containin a magnei li m ompound and a'drug of this barbituric acid group, the therapeutic properties of which are increased by the magnesium com pound; the magnesium compound being present in an amout such that the magneslum is at least 25% by weight of the drug present.
  • a pharmaceutical product comprising a 'synergic composition containing a magnesium com-pound and barbita'l, the therapeutic properties of which are increased by themagneslum compound, the magnesium compound being present in an amout such'that the magnesium is at least 25% by weight of the drug present.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

. 1,716,686, granted July 11 Patented Nov. 3,1931
UNITED STATES PATENT. ounce MOSES L CBOSSLEY, OF PLAINFIELD, NEW JERSEY, ASSIGNOR, BY KESNE ASSIGN- MIENTS, TO THE GALCO CHEMICAL COMPANY, INC A CORPORATION 01' DELAWARE mmmmb mrnrorrc m smwnvn R Drawing.
My invention relates particularly to improved pharmaceuticals having enhanced economic value and ,more extended use in chemotherapyfbut especiall it has relation to improvedhypnotics an sedatives containing one or more magnesium compounds which synergize the drugs present.
In my co-pending application, Serial No. 178,152, filed March 24,1927, Patent Number 1929, I have disclosed pharmaceuticals having enhanced therapeutic value owing to the synergizing of the drugs therein, having" known therapeutic properties, with magnesium compounds. As set forth therein, the therapeutic range of the drugs is increased by their otentiation due to the magnesium compoun s present. That is to say, a 'ven therapeutic effect can be attained, accor ing- 0 ly, with less of the potentiated dru than when unpotentiated, and with less anger to the patient from an toxic action on the human organism.- As have shown therein, furthermore, the potenti'ated drugs have a distinct economic advantage as compared with the unpotentiated drugs. Likewise, there is less tendency, when using the same, to cause secondary efiects than in the case of the unpotentiated drug, and, accordingly, the human system is better able to toleratethe drugs. I find, furthermore, that the drugs are also 1e s liable to accumulate in'the sys' tem inasmuch as the desired therapeutic effect can be obtained with smaller egoses;-which' 1 5 is a very decided advantage,
pecially in the case of haEit-forming drugs.
The object f my invention is to provide improved pharmaceuticals, and particularly those used because of their hypnotic and se-;i dative properties, inwhich the drugs have.
their therapeutic properties potentiated due to the presence of one or more magnesiumcompounds. f-The object of my invention is; more particularly, furthermore, to
4 provide a composition of this character a lication fled April 17, ms. Serial Io. 270,808.-
containin a drug of thelbarbituric acid series, the ormula for barbituricacid being which, by reason ofthe presence of a magnesium compound will produce their own therapeutic eflects with much less of the drug and in a shorter time than in the case of the unpotentiated drug. It is found, furthermore, that in using the composition made in accordance with my invention, the narcosis which results from the drug is less prolonged than with the unpotentiated drug. Also, the composition is less toxic in therapeutic doses than with the unpotentiated drug. With these com ositions containing hypnotic and sedative rugs, such, for example, as the drugs of the barbituric acid series,oneexample of which is bartital or some other hypnotic and-sedative such as bromatone, bromural, carbromal, chloral, sulfonal, etc., and containing one or more magnesium compounds as above referred to, such, for example, as
-magnesium chloride, magnesium sulfate,
magnesium oxide, magnesium lactate, margnesium gluconate, etc.,I may use other ad tionaL compositions which may or may not have a therapeutic effect. Such substances which may be added to enhance the absorptive properties of the composition are, for example, ethyl alcohol, glycerol, glycol, etc. Also, in all such compositions the magnesium compound ma vary in amount through wide limits, but I ave found very effective results .to be obtained by the use of the magnesium compound in an amount in which the magnesium present is at least 25% by weight of the, weight of the drug present.
My invention is capable of being carried out in many difierent ways but for the pur- I pose of illustration I shall describe onlycertain forms of carrying out the same in detail hereinafter. I i
For example, an effective composition made in accordance with my invention may contain 2 parts by weight of magnesium chloride and 1 part *by' weight of sodium barbital,
the formula of which isonset of the narcosis accelerated when using p said composition, but it is found that the animal recovers much more quickly as the narcosis is less prolonged. In many cases I have found that thenarcotic condition produced by the synergic combination is over in about one half the time required for the recovery by using the unpotentiated dose required to produce a similar degree of narcosis. Barbital alone is usually administered in 5 grain tablets. I have found that, instead, a tablet containing approximately 2 grains of-barbital and 5 grains of magnesium chloride or an equivalent weight of magnesium oxide, can be used with the same therapeutic effects. It will be understood that the proportion of the'magnesium compound used may be widely varied and may, for exam le, be increased to as large a quantity as found efiective for the purpose desired, or substituted by any other Imagnesium compound as above described. t will also be understood that any other one of the hypnotic and sedative drugs may be substituted for the barbital, if desired. Also, while 4 the composition above described, as well as those hereinafter referred to, or their components, may be administered per os, they may be administered in any other way, as, for
example, by injection (intravenously or intramuscularly) or by any suitable method, employed in medicine.
Again, it will be understood the synergic compositions may be made of the above character, but containing, also, some substance to increase the absorption, as, for example, aloohol, glycerine or glycol or some other suitable polyhydroxyl alcohol. A compositionof this character may be comprised of 0.2 parts by weight of sodium barbital, 0.4 parts by weight of magnesium' cbloride, and 30 parts by weight of- 2 2%" alcohol. If desired, there maybe added, also, 10'parts by weight of a sweetening agent, such as sucrose syrup.
this composition it will 'be understoodflof course, that any other hypnotic and sedative drug .may be substituted for the sodium barbital. Also, any other one of the above mentioned magnesium compounds may be substituted in an equivalent quantity for the magnesium chloride, and thatthe quantity of the magnesium compound may be varied. in the manner referred to in the above mentioned compositions. Also, the alcohol may be substituted by any other one of the substances'hereinabove referred to for increasing the absorption of the composition. In fact any of the above constituents may be substituted by others of a similar character for similar purposes.
It will be understood, of course, that in all of the above compositions theproportions of the various constituents may be varied widely without departing from the spirit of my invention.
Synergic compositions of the above character are particularly effective in. the case of insomnia .and similar maladies.
While I have described my invention above in detail I wish'it to be understood that many changes may be made therein without depart ing from the spirit of the same.
.I claim: 1. A pharmaceutical product comprising a synergic composition containing a magnesium compound and a synthetic hypnotic and sedative drug, the them utic properties of which are increased by t e magnesium com-- pound.
2. A pharmaceuticalproduct comprising a synergic composition containing a magnesium compound and a drug of the barbituric acid group, the therapeutic properties of which are lncreased pound.
3. A pharmaceutical product comprising a synergic composition containing a magneslum compound and barbital, the therapeutic properties of which are creased by the magnesium compound. 4. A harmaceutical product-comprising a ergic composition containing magnesium by the magnesium comc oride, a synthetic hypnotic and'sedative" drug, the therapeutic properties of which are increased b the magnesium chloride, and an aliphatic a cohol, Y
- 5. Apharmaceutical product comprisinga synerg c compositioncontainin magnesium chloride, a drug of the barbitune acid group,
the therapeutic properties of which are m-- creased by the magnesium chloride, and an aliphatic alcohol.
6. A pharmadeutical product comprising}; synergic. composition containin magnesium c loride,barbital, the therapeutic PFP of which are mcreasedby chloride, and an aliphatic alcohol.
. 7. A pharmaceutical product comprising a synergiccompos'ition containing a magne ,the magnesium sium com ound and a synthetic hypnotic and sedativeug, the-thera eufic properties of which are increased by the magnesium com- I pound,the magnesium compound bein pres- 5 cut in an al'nout such that the-magneslum is at least 25% by weight of the drug present. 8. A pharmaceutical product comprising a er ic composition containin a magnei li m ompound and a'drug of this barbituric acid group, the therapeutic properties of which are increased by the magnesium com pound; the magnesium compound being present in an amout such that the magneslum is at least 25% by weight of the drug present.
9'. A pharmaceutical product comprising a 'synergic composition containing a magnesium com-pound and barbita'l, the therapeutic properties of which are increased by themagneslum compound, the magnesium compound being present in an amout such'that the magnesium is at least 25% by weight of the drug present.
In testimony that I claim the foregoing, I have hereunto set' my hand this 12th day of 26 April, 1928. a v a 'MOSES L. GROSSLEY.
US270806A 1928-04-17 1928-04-17 Synergized hypnotic and sedative Expired - Lifetime US1830313A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US270806A US1830313A (en) 1928-04-17 1928-04-17 Synergized hypnotic and sedative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US270806A US1830313A (en) 1928-04-17 1928-04-17 Synergized hypnotic and sedative

Publications (1)

Publication Number Publication Date
US1830313A true US1830313A (en) 1931-11-03

Family

ID=23032875

Family Applications (1)

Application Number Title Priority Date Filing Date
US270806A Expired - Lifetime US1830313A (en) 1928-04-17 1928-04-17 Synergized hypnotic and sedative

Country Status (1)

Country Link
US (1) US1830313A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108997A (en) * 1957-10-31 1963-10-29 Astra Ab Morpholino lower alkanoyl xylidides and toluidides
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108997A (en) * 1957-10-31 1963-10-29 Astra Ab Morpholino lower alkanoyl xylidides and toluidides
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride

Similar Documents

Publication Publication Date Title
Vesselinovitch et al. Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice
US2770569A (en) Analgesic compositions
SE8402550D0 (en) N-SUBSTITUTED DERIVATE OF MORANOLINE
James et al. Effect of (±)-1, 2-bis (3, 5-dioxopiperazin-1-yl) propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma
GB1064629A (en) Alkene derivatives
US1830313A (en) Synergized hypnotic and sedative
Cosgriff The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy
DiPaolo et al. The comparison of teratogenic and carcinogenic effects of some carbamate compounds
ES433860A1 (en) 3-(4{40 -Alkoxy-benzoyl)-1,2,2-trimethylcyclopentane-carboxylic acids, methods of use and compositions containing such compounds
US1845486A (en) Synergized codein drugs
US2799619A (en) Anti-excitatory compositions
US2381830A (en) Medicinal preparation
US2744851A (en) Cardiac glycosides for intramuscular injection
US3085932A (en) Therapeutic composition comprising 3, 3-diethyl-5-methyl-2, 4-piperidinedione and 7-chloro-2-methylamino-5-phenyl-3h-1, 4-benzodiazepine-4-oxide
ANDERSON Potency and duration of action of triiodothyronine and thyroxine in rats and mice
US1716686A (en) Pharmaceutical
US2605209A (en) Solutions of barbituric compounds
Simeons et al. Preliminary report on a new synthetic antimalarial
JPH0499723A (en) Virus-genomic inactivator
US2376795A (en) Sulphapyridine composition of low toxicity
US2354738A (en) Parenteral solution of anti-hemorrhagic compounds
US2807566A (en) Method of potentiating drugs affecting the central nervous system and compositions therefor
US3629416A (en) Method of treating or preventing coccidiosis with thiosemicarbazone derivatives
US3422195A (en) Antihistaminic and motion sickness preventing compositions
DE3348493C2 (en) Di:hydro-poly:prenyl alcohol and ester and ether derivs.